FDA Clearance Tracker · P190031
HER2 Dual ISH DNA Probe Cocktail
Last checked: Nov 20, 2026Latest source record: Jul 28, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Jul 28, 2020
Approved (reclassified)
Time to decision
242 days
Received Nov 29, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P190031
- Device name
- HER2 Dual ISH DNA Probe Cocktail
- Applicant
- Ventana Medical Systems, Inc.
- Applicant location
- Tucson, AZ
- Received
- Nov 29, 2019
- Decided
- Jul 28, 2020
- Decision
- Approved (reclassified)
- Supplements
- 14 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer (NYQ)
- Device class
- Class II
- Regulation
- 21 CFR 864.1890
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the VENTANA HER2 Dual ISH DNA Probe Cocktail assay.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NYQ. The earliest in FDA's data is P050040, decided Jul 1, 2008.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Ventana Medical Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- VENTANA HER2 Dual ISH DNA Probe CocktailPMA supplement
P190031-S016 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer (NYQ) · Laboratory Medicine & Pathology
P990081-S060 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: SYSTEM, TEST, HER-2/NEU, IHC (MVC) · Laboratory Medicine & Pathology
P250031 · Decided Jun 12, 2026 · 298 days after receipt
Device type: Immunohistochemistry Assay, Antibody (SHF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.